Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis
Giampaolo Merlini, Violaine Planté-Bordeneuve, Daniel P Judge, Hartmut Schmidt, Laura Obici, Stefano Perlini, Jeff Packman, Tara Tripp, Donna R Grogan, Giampaolo Merlini, Violaine Planté-Bordeneuve, Daniel P Judge, Hartmut Schmidt, Laura Obici, Stefano Perlini, Jeff Packman, Tara Tripp, Donna R Grogan
Abstract
This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, efficacy, and safety of tafamidis in patients with non-Val30Met transthyretin (TTR) amyloidosis. Twenty-one patients with eight different non-Val30Met mutations received 20 mg QD of tafamidis meglumine for 12 months. The primary outcome, TTR stabilization at Week 6, was achieved in 18 (94.7%) of 19 patients with evaluable data. TTR was stabilized in 100% of patients with non-missing data at Months 6 (n = 18) and 12 (n = 17). Exploratory efficacy measures demonstrated some worsening of neurological function. However, health-related quality of life, cardiac biomarker N-terminal pro-hormone brain natriuretic peptide, echocardiographic parameters, and modified body mass index did not demonstrate clinically relevant worsening during the 12 months of treatment. Tafamidis was well tolerated. In conclusion, our findings suggest that tafamidis 20 mg QD effectively stabilized TTR associated with several non-Val30Met variants.
Trial registration: ClinicalTrials.gov NCT00630864.
Figures
References
- Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nature Reviews Cardiology. 2010;7:398–408. doi: 10.1038/nrcardio.2010.67.
- Blake CC, Geisow MJ, Swan ID, Rerat C, Rerat B. Structure of human plasma prealbumin at 2–5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. Journal of Molecular Biology. 1974;88:1–12. doi: 10.1016/0022-2836(74)90291-5.
- Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein. Science. 1995;268:1039–1041. doi: 10.1126/science.7754382.
- Mita S, Maeda S, Shimada K, Araki S. Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy. Journal of Biochemistry. 1986;100:1215–1222.
- Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. FEBS Letters. 2001;498:201–203. doi: 10.1016/S0014-5793(01)02480-2.
- Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(Suppl 4):16427–16432. doi: 10.1073/pnas.202495199.
- Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713–716. doi: 10.1126/science.1079589.
- Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS Journal. 2007;274:1637–1650. doi: 10.1111/j.1742-4658.2007.05712.x.
- Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases. 2013;8:31. doi: 10.1186/1750-1172-8-31.
- Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. pp. 88–98.
- Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurology. 2011;10:1086–1097. doi: 10.1016/S1474-4422(11)70246-0.
- Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10:160–184. doi: 10.3109/13506120308998998.
- Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Human Mutation. 2001;17:493–503. doi: 10.1002/humu.1132.
- Wilczek HE, Larsson M, Ericzon BG. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) Amyloid. 2011;18(Suppl 1):193–195. doi: 10.3109/13506129.2011.574354072.
- Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective. European Heart Journal. 2013;34:520–528. doi: 10.1093/eurheartj/ehs123.
- Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30) Clinical Genetics. 1991;40:242–246. doi: 10.1111/j.1399-0004.1991.tb03085.x.
- Skinner M, Lewis WD, Jones LA, Kasirsky J, Kane K, Ju ST, et al. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Annals of Internal Medicine. 1994;120:133–134. doi: 10.7326/0003-4819-120-2-199401150-00006.
- Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: Results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004;77:64–71. doi: 10.1097/01.TP.0000092307.98347.CB.
- Takei Y, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, Ando Y. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: Outcomes of living donor liver transplantations. Internal Medicine. 2005;44:1151–1156. doi: 10.2169/internalmedicine.44.1151.
- Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation. 1997;64:74–80. doi: 10.1097/00007890-199707150-00014.
- Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: Implications for amyloid fibrillogenesis. Transplantation. 1998;66:229–233. doi: 10.1097/00007890-199807270-00016.
- Arpesella G, Chiappini B, Marinelli G, Mikus PM, Dozza F, Pierangeli A, et al. Combined heart and liver transplantation for familial amyloidotic polyneuropathy. Journal of Thoracic and Cardiovascular Surgery. 2003;125:1165–1166. doi: 10.1067/mtc.2003.151.
- Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:9629–9634. doi: 10.1073/pnas.1121005109.
- Coelho T, Maia L, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology. 2012;79:785–792. doi: 10.1212/WNL.0b013e3182661eb1.
- Packman, J., Fleming, J. N., Souther, E., Grogan, D. R. (2010). Stabilization of transthyretin by tafamidis in transthyretin amyloidosis across different amyloidogenic variants. Paper presented at the The Annual Meeting of the American Society of Human Genetics; November 2–6, 2010, Washington, DC, USA.
- Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O’Brien PC. Variables influencing neuropathic endpoints: The Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology. 1995;45:1115–1121. doi: 10.1212/WNL.45.6.1115.
- Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care. 2007;30:896–902. doi: 10.2337/dc06-1699.
- Dyck PJ, Karnes JL, O’Brien PC, Litchy WJ, Low PA, Melton LJ., 3rd The Rochester Diabetic Neuropathy Study: Reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164–1170. doi: 10.1212/WNL.42.6.1164.
- Dyck PJ, Davies JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997;49:229–239. doi: 10.1212/WNL.49.1.229.
- Dyck PJ, O’Brien PC, Litchy WJ, Harper CM, Klein CJ. Monotonicity of nerve tests in diabetes: Subclinical nerve dysfunction precedes diagnosis of polyneuropathy. Diabetes Care. 2005;28:2192–2200. doi: 10.2337/diacare.28.9.2192.
- Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technology & Therapeutics. 2005;7:497–508. doi: 10.1089/dia.2005.7.497.
- Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. Journal of Internal Medicine. 1994;235:479–485. doi: 10.1111/j.1365-2796.1994.tb01106.x.
- Lehrke S, Steen H, Kristen AV, Merten C, Lossnitzer D, Dengler TJ, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: New evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid. 2009;16:187–195. doi: 10.3109/13506120903421538.
- Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography. 2005;18:1440–1463. doi: 10.1016/j.echo.2005.10.005.
- Januzzi JL, Jr, Sakhuja R, O’Donoghue M, Baggish AL, Anwaruddin S, Chae CU, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Archives of Internal Medicine. 2006;166:315–320. doi: 10.1001/archinte.166.3.315.
- Januzzi JL, Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. American Journal of Cardiology. 2005;95:948–954. doi: 10.1016/j.amjcard.2004.12.032.
- Behnes M, Brueckmann M, Ahmad-Nejad P, Lang S, Wolpert C, Elmas E, et al. Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. International Journal of Cardiology. 2009;135:165–174. doi: 10.1016/j.ijcard.2008.03.045.
- Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. American Journal of Hematology. 2005;79:319–328. doi: 10.1002/ajh.20381.
- Suhr OB, Ericzon BG, Friman S. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type) Liver Transplantation. 2002;8:787–794. doi: 10.1053/jlts.2002.34386.
- Coelho T, Chorao R, Sousa A, Alves I, Torres M, Saraiva M. Compound heterozygotes of transthyretin Met 30 and transthyretin Met 119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscular Disorders. 1996;6(Suppl 1):S20. doi: 10.1016/0960-8966(96)88826-2.
- Terazaki H, Ando Y, Misumi S, Nakamura M, Ando E, Matsunaga N, et al. A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochemical and Biophysical Research Communications. 1999;264:365–370. doi: 10.1006/bbrc.1999.1514.
- Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293:2459–2462. doi: 10.1126/science.1062245.
- Falk, R. H., Maurer, M. S., Fedson, S. E., Judge, D., Zeldenrust, S., Quyymi, A., Pano, A., Packman, J., Grogan, D. R. (2011). Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes. Paper presented at the Heart Failure Society of America—15th Annual Scientific Meeting, September 18–21, 2011, Boston, MA, USA.
Source: PubMed